Dyax discontinues ecallantide Phase II trial

Dyax Corp. (NASDAQ:DYAX) discontinued a Phase II trial of ecallantide to treat of angiotensin-converting enzyme (ACE) inhibitor-induced angioedema after an interim analysis did not show a significant ...